Drug errors are unfortunately a major source of iatrogenic harm for patients in the hospital and in the operating rooms and are challenging to study due to most analyses being based on self-recognition and reporting by staff members. Estimates have... Read More +
Drug errors are unfortunately a major source of iatrogenic harm for patients in the hospital and in the operating rooms and are challenging to study due to most analyses being based on self-recognition and reporting by staff members. Estimates have suggested adverse drug events (ADEs) account for 7,000 deaths annually in the United States. The annual cost of drug-related errors for a 700-bed teaching hospital has been estimated at approximately $5.6 million.
In this course, you’ll learn about adverse drug events in hospitalized patients, adverse drug events in operating room patients, types of drug errors, a review of closed claims data, and strategies for reducing medication errors.Close —
The American Society of Anesthesiologists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Anesthesiologists designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification in Anesthesiology® and MOCA® are registered certification marks of the American Board of Anesthesiology®. MOCA 2.0® is a trademark of the American Board of Anesthesiology®.
This activity contributes to the patient safety CME requirement for the CME component of the American Board of Anesthesiology’s (ABA) redesigned Maintenance of Certification in Anesthesiology® (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.
At the conclusion of this activity, participants should be able to:
Jonathan Cohen, MD
Delcath Systems, Inc. – Consultant
Jeffrey Green, MD, MSHA, FASA
Cerus Corporation – Grant / Contract
La Jolla Pharmaceutical Company – Consultant
Medtronic – Consultant
Senthilkumar Sadhasivam, MD, MPH, MBA, FASA
NeurOptics – Consultant
All relevant financial relationships for this activity have been mitigated. All other planners, authors, editors, and staff have disclosed no relevant financial relationships with commercial interests.